Dorzolamide hydrochloride with timolol maleate, eye drops
Brand: Cosopt® Preservative Free Eye Drops
PBAC's latest decision on Dorzolamide hydrochloride with timolol maleate, eye drops: Recommended with restriction (2012). Considered for reduction of elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension that is not adequately controlled with monotherapy.
PBAC outcome
Recommended with restriction
Restricted Benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2012
Submissions
1
2012 → 2012
Eligible population
patients with open-angle glaucoma or ocular hypertension that is not adequately controlled with monotherapy
Therapy area
Ophthalmology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
OS | PFS | DFS | ORR | QoL | Surrogate | Cost-minimisation | Other | null
Pivotal trial size
261 patients
Key trials
P081
Comparator
preservative containing dorzolamide with timolol (PC-dorz/tim)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated